

# Update on surfactant treatment in newborns, infants and children

Giuseppe A. Marraro, MD  
[gmarraro@picu.it](mailto:gmarraro@picu.it)      [www.picu.it](http://www.picu.it)

## Bibliography

1. Auten R, Notter RH, Kending JW, Davis JM, Shapiro DL. Surfactant treatment of full term newborns with respiratory failure. *Pediatrics* 1991; 87:101-107
2. Avery M.E. & Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. *Am J Dis Child* 1959; 97:517-523
3. Balaraman V, Sood SI, Finn KC, Hashiro G, Uyehara CFT, Easa D. Physiologic response and lung distribution of lavage versus bolus Exosurf in piglets with acute lung injury. *Am J Respir Crit Care Med* 1996; 153:1883-1843
4. Bun B, Curstedt T, Robertson B. Surfactant inhibition in experimental meconium aspiration syndrome. *Acta Paediatr* 1993; 82:182-189
5. Cleary GM, Wiswell TE. Meconium-stained amniotic fluid and the meconium aspiration syndrome - an update. *Pediatr Clin North Am* 1998; 45:511-529
6. Clements J.A. Surface tensions of lung extracts. *Proc. Soc Exp Biol Med* 1957; 95:170-172
7. Clements J.A. Surface phenomena in relation to pulmonary function. *Physiologist* 1962; 5:11-28
8. Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. *Pediatrics* 1988; 82:683-691
9. Dargaville PA, South M, Mac Douglas PN. Surfactant abnormalities in infants with severe viral bronchiolitis. *Arch Dis Child* 1996; 75:133-136
10. Enhoerning G, Robertson B. Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. *Pediatrics* 1972; 50:55-56
11. Foust R III, Tran NN, Cox C, Miller TF, Greenspan JS, Wolfson MR, Shaffer TH. A liquid assisted ventilation: an alternative ventilation strategy for acute meconium aspiration injury. *Pediatr Pulmonol* 1996; 21:316-322
12. Fuchimukai T, Fujiwara T, Takahashi A, Enhoerning G. Artificial pulmonary surfactant inhibited by proteins. *J Appl Physiol* 1987, 62:429-437
13. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyaline membrane disease. *Lancet* 1980; 1:55-59
14. Greenough A. Expanded use of surfactant replacement therapy. *Eur J Pediatr* 2000; 159:635-640
15. Gregory GA, Kitterman JA, Phibbs RA, Tooley WH, Hamilton WK. Treatment of idiopathic respiratory distress syndrome with continuous positive airway pressure. *N Engl J Med* 1971; 284:1333-1340
16. Gruenwald P. Surface tension as a factor in the resistance of neonatal lungs to aeration. *Am J Obstet Gynecol* 1947; 53:996-1007
17. Halliday HL. Overview of clinical trials comparing natural and synthetic surfactants. *Biol Neonate* 1995; 67 (S1): 32-47
18. Halliday HL, Speer c, Robertson B on behalf of the collaborative Surfactant Study Group. Treatment of severe meconium aspiration syndrome with porcine surfactant. *Eur J Pediatr* 1996; 155:1047-1051
19. Halliday HL. Clinical trials of surfactant replacement in Europe. *Biol Neonate* 1997; 71(S1):8-12

20. Hallman M, Merritt TA, Jarvenpaa AL, Boyton B, Mannino F, Gluck L, Moore T, Edwards D. Exogenous human surfactant for treatment of severe respiratory distress syndrome. a randomized prospective clinical trial. *J. Pediatr* 1985; 106:963-969
21. Hallman M, Merritt TA, Pohjavuori M, Gluck L. Effect of surfactant substitution on lung effluent phospholipids in respiratory distress syndrome. Evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure. *Pediatr Res* 1986, 20:1228-1235
22. Herting E, Jarstrand C, Rasool O, Curstedt T, Sun B, Robertson B. Experimental neonatal group B streptococcal pneumonia: effect of a modified porcine surfactant on bacterial proliferation in ventilated near-term rabbits. *Pediatr Res* 1994; 36:784-791
23. Herting E, Gefeller O, Land M, van Sonderen L, Harms K, Robertson B and Members of the Collaborative European Multicenter Study Group. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. *Pediatrics* 2000; 106:957-964
24. Hoekstra RE, Ferrara TB, Payne NR. Effects of surfactant therapy on outcome of extremely premature infants. *Eur J Paediatr* 1994; 153 (S2):12-16
25. Holm B, Notter R, Siegle J, Matalon S. Pulmonary physiological and surfactant changes during injury and recovery from hyperoxia. *J Appl Physiol* 1985; 59:1402-1409
26. Holm BA, Keicher L, Liu MY, Sokolowski J, Enhorning G. Inhibition of pulmonary surfactant function by phospholipases. *J Appl Physiol* 1991; 71:317-321
27. Ikegami M, Adams FH, Towers B, Other AB. The quantity of natural surfactant necessary to prevent the respiratory distress syndrome in premature lambs. *Pediatr Res* 1980, 14: 1082-1085
28. Jobe A, Ikegami M. Surfactant for the treatment of respiratory distress syndrome. *Am Rev Respir Dis* 1987, 136:1256-1275
29. Jobe AH. Pulmonary surfactant therapy. *N Engl J Med* 1993; 328:861-868
30. Khammash H, Pearlman M, Wojtulewicz J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. *Pediatrics* 1993; 92:135-139
31. Kobayashi T, Nitta K, Ganzuka M, Inui S, Grossman G, Robertson B. Inactivation of exogenous surfactant by pulmonary edema fluid. *Pediatr Res* 1991, 29:353-356
32. Lachmann B. Surfactant replacement. *Applied Cardiopulmonary Pathophys* 1989;3:3-11
33. Lam BCC, Yeung CY. Surfactant lavage for meconium aspiration syndrome - a pilot study. *Pediatrics* 1999; 103:1014-1018
34. Lam BCC. Surfactant lavage for the management of severe meconium aspiration syndrome. *Biol Neonate* 1999; 76(S1): 10-14
35. Le Vine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA, Korfhagen T. Surfactant protein A-deficient mice are susceptible to group B streptococcal infection. *J. Immunol* 1997; 158:4336-4340
36. Lewis JF, Ikegami M, Jobe AH. Altered surfactant function and metabolism in rabbits with acute lung injury. *J Appl Physiol* 1990; 69:2303-2310
37. Lewis J, Ikegami M, Higuchi R, Jobe A, Absolom D. Nebulized vs. instilled exogenous surfactant in an adult lung injury model. *J Appl Physiol* 1991 ;71:1270-1276
38. Lewis J, Tabor B, Ikegami M, Jobe A, Joseph M, Absolom D. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs. nebulized surfactant. *J Appl Physiol* 1993; 74:1256-1264
39. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. *Am Rev Respir Dis* 1993; 147:218-233
40. Liggins GC. Premature delivery of foetal lambs infused with glucocorticoids. *J Endocrinol* 1969; 45:515-523
41. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. *Pediatrics* 1972, 50:515-525

42. Lopez-Herce J, de Lucas N, Carrillo A, Bustinza A, Moral R. Surfactant treatment for acute respiratory distress syndrome. *Arch Dis Child* 1999; 80:248-252
43. Lotze A, Mitchell BR, Bulas DI, Hull WM, O'Donnell RM, Whisett JA, Short BL, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (Beractant) use in the treatment of term infants with severe respiratory failure. *J Pediatr* 1998;132:40-47
44. Luchetti M, Casiraghi G, Valsecchi R, Galassini E, Marraro G. Porcine-derived surfactant treatment of severe bronchiolitis. *Acta Anaesthesiol Scand* 1998; 42:805-810
45. MacIntyre NR, Coleman RE, Schuller FS, Zacardelli D, Pattishall E. Efficiency of the delivery of aerosolized surfactant to intubated patients with ARDS. *Am Rev Resp Dis* 1994; 149:A125
46. Marks LB, Notter RH, Oberdorster G, McBride JT. Ultrasonic and jet aerosolization of phospholipids and the effect on surface activity. *Pediatr Res* 1983, 17:742-747
47. Marraro G, Casiraghi G, Riva A. Effets d'un apport de surfactant chez deux adolescents leucémiques atteints de détresse respiratoire. *Cah Anesthesiol* 1991; 4:227-232
48. Marraro G, Foresti B, Casiraghi G, Monici-Preti P. Follow up of infants treated with porcine surfactant replacement for severe neonatal and infant respiratory distress syndrome: antigenic reactivity evaluation. *Drugs Exptl Clin Res* 1991; XVII(10/11):511-515
49. Marraro G, Foresti B, Casiraghi G, Riva A. Surfactant treatment of respiratory failure in children. In Bevilacqua G et al. Eds "Surfactant in clinical practice". Harwood Acad Publish 1992; 173-180
50. Marraro G. Emploi du surfactant dans la pathologie respiratoire du nouveau-né et du nourisson. *Cah Anesthesiol* 1994; 2:159-166
51. Marraro G, Casiraghi G, Marinari M, Valsecchi R, Riva A. L'impiego del surfattante naturale nel trattamento della sindrome d'aspirazione massiva di liquido amniotico del neonato.(Natural surfactant application in meconium aspiration syndrome of the newborns). *Neonatologica* 1994; 4:299-308
52. Marraro G. Use of surfactant in ARDS. *J Anaesth Clin Pharmacol* 1995; 11:275-278
53. Marraro G, Casiraghi G, Galbiati AM. A study of pressure regulated volume control ventilation in natural surfactant treated infants with RDS. *Ped Research* 1995;37(n4):223A, 1321
54. Marraro G, Casiraghi G, Riva A, Galbiati A. L'impiego del surfattante naturale suppletivo nell'Adult Respiratory Distress Syndrome (ARDS) del bambino (Natural surfactant supplementation in infants affected by like-Adult Respiratory Distress Syndrome). *Riv Ital Pediatr (IJP)* 1995; 21:284-289
55. Marraro G, Bonati M, Ferrari A, Barzaghi MM, Pagani C, Bartolotti A, Galbiati A, Luchetti M, Croce a. Perfluorocarbon broncho-alveolar lavage and liquid ventilation versus saline broncho-alveolar lavage in adult guinea pig experimental model of meconium inhalation. *Intensive Care Med* 1998; 24:501-508
56. Marraro G, Galassini EM, Padovani EM. Independent lung ventilation and exogenous surfactant in congenital diaphragmatic hernia complicated by unilateral lung pathology. *Biol Neonate* 1998; 74 (S1):47
57. Marraro G. Natural Surfactant supplementation in ARDS in paediatric age. *Minerva Anesthesiol* 1999; 65 (suppl 1): 92-97
58. Pattle R.E. Properties, function and origin of the alveolar lining layer. *Nature* 1955; 175:1125-1126
59. Raju TK, Vidyasagar D, Bhat R, Sobel D, McCulloch KM, Anderson M, Maeta H, Levy PS. Double-blind controlled trial of single-dose treatment with bovine surfactant in severe hyaline membrane disease. *Lancet* 1987; 1:651-656
60. Reiss I, Woessmann W, Kohl M, Ahrens P, Moeller JC, Gortner L. Bronchoscopic administration of surfactant with an ultrathin fibre bronchoscope in infants with chronic lung disease and persistent atelectasis. *Biol Neonate* 1999; 76 (S1):44-45

61. Schermuly R, Schmehl T, Gunther A, Grimminger F, Seeger W, Walmrath D. Ultrasonis nebulisation for efficient delivery of surfactant in a model of acute lung injury. *Am J Resp Crit Care Med* 1997; 156:445-453
62. Seeger W, Lepper H, Wolf HRD, Neuhoef H. Alteration of alveolar surfactant function after exposure to oxidative stress and to oxygenated and native arachidonic acid in vitro. *Biochim Biophys Acta* 1985; 835:58-67
63. Seeger W, Lepper H, Wolf HRD, Neuhoef H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. *J Appl Physiol* 1985; 56:326-338
64. Shapiro DL, Notter RH, Morin FC 3rd, Deluga KS, Golub LM, Sinkin RA, Weiss KI, Cox C. Double-blind, randomised trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. *Pediatrics* 1985, 76:593-599
65. Sherman MP, Campbell LA, Merritt TA, Long WA, Gunkel JH, Curstedt T, Robertson B. Effect of different surfactant on pulmonary group B streptococcal infection in premature rabbits. *J Pediatr* 1994; 125:939-947
66. Skelton R, Holland P, Darowski M, Chetcuti PA, Morgan LW, Harwood JL. Abnormal surfactant composition and activity in severe bronchiolitis. *Acta Paediatr* 1999; 88:942-946
67. Smyth J, Allen A, Mac Murray B, Peliowski A, Sankaran K, Volbert F, Shukla A, Long W, Canadian Exosurf Neonatal Study Group: double blind, randomized, placebo controlled Canadian multicenter trial of two doses of synthetic surfactant or air placebo in 224 infants weighing 500-749 grams with respiratory distress syndrome. *J Pediatr* 1995; 126:581-589
68. Soll RF. Surfactant treatment of the very preterm infant. *Biol Neonate* 1998; 74 (S1):35-42
69. Spragg RG. Surfactant therapy in acute respiratory distress syndrome. *Biol Neonate* 1998; 74(S1):15-20
70. Steinberg KP. Surfactant therapy in the adult respiratory distress syndrome. *Respir Care* 1993; 38:365-372
71. Strayer DS, Merritt TA, Hallman M. Surfactant replacement: immunological consideration. *Eur Respir J* 1989; 3(S2):91-96
72. Taeusch HW. Treatment of acute (Adult) respiratory distress syndrome. The holy Grail of surfactant therapy. *Biol Neonate* 2000; 77(S1):2-8
73. Tibby SM, Hatherill M, Wright SM, Wilson P, Poste AD, Murdoch IA. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. *Am J Respir Crit Care Med* 2000; 162:1251-1256
74. Valls i Soler A, Fernandez-Ruanova B, Robertson B on behalf of the collaborative Surfactant Study Group. Recent Advances in Surfactant Research. *Biol Neonate* 1998; 74 (S1):54-55
75. Van Daal GJ, So KL, Gommers D, Eijking EP, Fievez RB, Sprenger MJ et al. Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia. *Anesth Analg* 1991; 72:589-595
76. Van Schaik SM, Vargas I, Welliver RC, Enhoerning G. Surfactant dysfunction develops in BALB/c mice infected with respiratory syncytial virus, *Pediatr Res* 1997; 42:169-173
77. Von Neergaard K. Neue Auffassungen uber einen Grundbegriff der Atemmechanik. Die Retraktionskraft der Lunge, abhaengig von der Oberflaechenspannung in den Alveolen. *Z. Gesant Exp Med* 1929; 66:373-394
78. Walmrath D, Gunther A, Ghofrani HA, Schermuly R, Schneider T, et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. *Am J Respir Crit Care Med* 1996; 154:57-62
79. Walsh W, Paranka M. Treatment of meconium aspiration in piglets with surfactant lavage. *Am J Perinatol* 1992; 9:506-507